Pulmonary alveolar proteinosis: 2026 so far

A stronger trial summary helped clarify the likely benefits and limits.

In the months covered, a pooled analysis of four phase III randomized trials (a late-stage trial testing whether a treatment works and is safe) strengthened evidence that inhaled GM-CSF improves gas exchange/oxygen-related measures and dyspnea (shortness of breath) in adults with autoimmune PAP. The same analysis also clarified what did not show clear improvement: lung volume measures and exercise capacity. Elsewhere in 2026, case reports and cohorts continued to describe different individual courses, including relapse after improvement in some reports. Still, the most consistent higher-quality signal was better oxygen transfer and less breathlessness, which helps set expectations for which symptoms and tests are most likely to change with inhaled GM-CSF.

Research covered in: April 2026, February 2026, March 2026, June 2026, August 2026, January 2026

Reports added detail on how lavage is performed and monitored.

In reports from January 2026 to September 2026, whole-lung lavage (WLL) (washing out one lung under anesthesia) was repeatedly described as followed by improved symptoms and oxygenation in many autoimmune PAP patients. Some people needed repeat procedures. Several reports focused on how WLL is delivered: a modified gravity-driven WLL approach shortened lavage and anesthesia time without higher reported complication rates, and physiologic work described predictable oxygen swings during the instillation versus drainage phases. A retrospective 40-patient comparison reported larger improvements when WLL was performed with ECMO support (a heart-lung machine that supports oxygenation) plus inhaled GM-CSF versus WLL plus GM-CSF without ECMO, but it was not randomized and could not separate ECMO effects from group differences. Overall, these updates mainly inform how WLL may be carried out and watched closely, especially in severe cases, rather than proving one WLL strategy is best.

Research covered in: March 2026, April 2026, July 2026, September 2026, June 2026, May 2026, August 2026

More reports connected complications and scarring with harder-to-treat disease.

A long-term real-world cohort found that pulmonary fibrosis (lung scarring) was linked to loss of treatment benefit and worse survival in autoimmune PAP. This link held regardless of whether patients received inhaled GM-CSF or lavage-based strategies. Case-based reports also described complicated courses where infections or overlapping conditions affected the timing and predictability of procedures and outcomes. These included reports of opportunistic infections (infections that take advantage of a weakened lung environment) around WLL and nocardiosis (a Nocardia bacterial infection) occurring alongside PAP, with outcomes ranging from improvement to death. A small imaging study linked more extensive CT involvement to measures suggesting higher right-heart load, and transient right-heart strain around WLL was described in a few patients. Together, these findings highlight that scarring, infections, and heart-lung strain can change what a 'response' looks like and how much support is needed during care.

Research covered in: July 2026, March 2026, April 2026, September 2026

Reports added options for confirming autoimmune PAP and for genetic workups in children.

In the months covered, reports added practical information for figuring out what type of PAP someone has. One report found that a newer blood GM-CSF autoantibody assay (a blood test for antibodies that block GM-CSF) matched a reference method and detected all clinically confirmed autoimmune PAP cases studied. However, positives were also reported in some disseminated Cryptococcus (a serious fungal infection) or Nocardia infections, which can complicate interpretation in certain settings. In children, a large cohort reported the highest genetic diagnostic yield in the subgroup labeled PAP, and having two or more non-lung organ findings increased the likelihood of an underlying systemic disease. Other early diagnostic-support signals included CT-based modeling to distinguish nodular PAP from early lung adenocarcinoma (a type of lung cancer) and a small report suggesting Napsin-A staining (a lab stain that highlights certain cells) on bronchoalveolar lavage samples (fluid collected from the lungs during bronchoscopy) could support diagnosis when specialized testing is unavailable. These updates mainly affect how confidently clinicians can classify the PAP subtype and avoid look-alike conditions, which can shape later management choices.

Research covered in: May 2026, January 2026, March 2026, August 2026

Early studies pointed to differences in antibody behavior and immune-cell pathways.

So far in 2026, one detailed antibody study suggested that autoimmune PAP severity may depend on anti-GM-CSF antibody class and binding affinity (how tightly an antibody sticks to its target), not just total antibody level. It also showed that high-affinity class 1 antibodies could induce PAP in a specialized mouse model. Several preclinical studies (lab and animal studies, not human trials) continued to point to problems in alveolar macrophages (lung immune cells that clear surfactant) and how the lungs handle lipids/surfactant. These included mTOR pathway disruption (a cell-growth signaling pathway) causing PAP-like changes in mice, and experimental delivery approaches such as inhaled GM-CSF mRNA and intranasal GM-CSF gene-delivery that improved PAP-like markers in animal models, with dose/safety questions noted. These findings are not clinical proof of new treatments, but they help explain why PAP can behave differently between people and why most new therapy ideas are still at the preclinical stage.

Research covered in: June 2026, February 2026, May 2026, August 2026, July 2026